3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
221
Polycystic Ovary Syndrome
36
Endometrial Neoplasms
15
Ovarian Neoplasms
13
Infertility
11
Neoplasm Metastasis
9
Carcinoma, Intraductal, Noninfiltrating
7
Fallopian Tube Neoplasms
6
Neoplasms
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Osteoporosis
4
Leiomyoma
4
Infertility, Female
4
Breast Neoplasms, Male
4
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Recurrence
3
Obesity
3
Breast Cancer Metastatic
3
Anovulation
3
Uterine Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Pancreatic Neoplasms
2
Pain
2
Leiomyosarcoma
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Interventions
Sirolimus
9
Everolimus
3
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphangioleiomyomatosis
×
Letrozole
×
Clear all
NCT01353209
2024-04-17
TRAIL
University of Cincinnati
Phase 2
Completed
17 enrolled
13 charts